Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 17c4a716-a22e-486d-b633-4be6c2453266

TECARTUS

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2026-06-16
Captured
2026-09-09T23:37:39.774134+00:00
Current indication reconciliation
Not reconciled
Boxed warning in this label
  1. WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, and SECONDARY HEMATOLOGICAL MALIGNANCIES Cytokine Release Syndrome (CRS), including life-threatening reactions, occurred in patients receiving TECARTUS. Do not administer TECARTUS to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids [see Dosage and Administration (2.2 , 2.3) , Warnings and Precautions (5.1) ] . Neurologic toxicities, including life-threatening reactions, occurred in patients receiving TECARTUS, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with TECARTUS. Provide supportive care and/or corticosteroids, as needed [see Dosage and Administration (2.2 , 2.3) , Warnings and Precautions (5.2) ] . T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies [see Warnings and Precautions (5.8) ] . WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, AND SECONDARY HEMATOLOGICAL MALIGNANCIES See full prescribing information for complete boxed warning. Cytokine Release Syndrome (CRS), including life-threatening reactions, occurred in patients receiving TECARTUS. Do not administer TECARTUS to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids ( 2.2 , 2.3 , 5.1 ). Neurologic toxicities, including life-threatening reactions, occurred in patients receiving TECARTUS, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with TECARTUS. Provide supportive care and/or corticosteroids, as needed ( 2.2 , 2.3 , 5.2 ). T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies ( 5.8 ).

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL). Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 1.1 Mantle Cell Lymphoma TECARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). 1.2 Acute Lymphoblastic Leukemia TECARTUS is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Full extracted label fields
application numbers
  1. BLA125703
boxed warning exact
  1. WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, and SECONDARY HEMATOLOGICAL MALIGNANCIES Cytokine Release Syndrome (CRS), including life-threatening reactions, occurred in patients receiving TECARTUS. Do not administer TECARTUS to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids [see Dosage and Administration (2.2 , 2.3) , Warnings and Precautions (5.1) ] . Neurologic toxicities, including life-threatening reactions, occurred in patients receiving TECARTUS, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with TECARTUS. Provide supportive care and/or corticosteroids, as needed [see Dosage and Administration (2.2 , 2.3) , Warnings and Precautions (5.2) ] . T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies [see Warnings and Precautions (5.8) ] . WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, AND SECONDARY HEMATOLOGICAL MALIGNANCIES See full prescribing information for complete boxed warning. Cytokine Release Syndrome (CRS), including life-threatening reactions, occurred in patients receiving TECARTUS. Do not administer TECARTUS to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids ( 2.2 , 2.3 , 5.1 ). Neurologic toxicities, including life-threatening reactions, occurred in patients receiving TECARTUS, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with TECARTUS. Provide supportive care and/or corticosteroids, as needed ( 2.2 , 2.3 , 5.2 ). T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies ( 5.8 ).
brand names
  1. TECARTUS
current indication status
not_reconciled
dailymed set url
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a16108c2-7ca7-45af-965e-54bda4713022
generic names
  1. BREXUCABTAGENE AUTOLEUCEL
id
17c4a716-a22e-486d-b633-4be6c2453266
indications and usage exact
  1. 1 INDICATIONS AND USAGE TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL). Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 1.1 Mantle Cell Lymphoma TECARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). 1.2 Acute Lymphoblastic Leukemia TECARTUS is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
indications and usage tables exact
    is original packager
    1. true
    manufacturer names
    1. Kite Pharma, Inc.
    matched search terms
    1. lymphoma
    2. leukemia
    package ndcs
    1. 71287-219-01
    2. 71287-219-02
    3. 71287-220-01
    4. 71287-220-02
    product ndcs
    1. 71287-219
    2. 71287-220
    product types
    1. CELLULAR THERAPY
    recent major changes exact
    1. Dosage and Administration ( 2.2 , 2.3 ) 06/2025 Warnings and Precautions ( 5.1 , 5.2 , 5.5 , 5.6 , 5.7 , 5.10 ) 04/2026 Warnings and Precautions, YESCARTA and TECARTUS REMS (5.3) Removed 06/2025
    record type
    complete_spl_indications_section_candidate
    routes
    1. INTRAVENOUS
    rxcuis
    1. 2387347
    2. 2387352
    3. 2572002
    4. 2572005
    source batch
    file
    /private/tmp/cancer-full-research/indications/raw/labels-00000.json
    meta
    disclaimer
    Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
    last updated
    2026-09-09
    results
    limit
    100
    skip
    0
    total
    830
    sha256
    0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
    url
    https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=0&sort=id%3Aasc
    source url
    https://api.fda.gov/drug/label.json?search=id%3A%2217c4a716-a22e-486d-b633-4be6c2453266%22
    spl effective date
    2026-06-16
    spl effective time
    20260616
    spl set id
    a16108c2-7ca7-45af-965e-54bda4713022
    spl version
    17
    substance names
    1. BREXUCABTAGENE AUTOLEUCEL
    uniis
    1. 4MD2J2T8SJ
    verification flags
    1. oncology_keyword_candidate_not_clinically_classified
    2. spl_text_not_verified_identical_to_latest_approved_label
    3. individual_indications_not_split_or_reconciled
    4. no_matched_approved_submission
    5. application_missing_from_drugsfda_bulk
    Drugs@FDA application source records
    1. application number
      BLA125703
      payload
      all indexed label documents
        all submission records
          application number
          BLA125703
          approval interpretation
          Application linkage and approved submission are not indication-level current approval verification
          current indication status
          not_reconciled
          has approved submission record
          false
          latest approved submission date
          Source null
          latest label selection rule
          max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
          latest posted label documents
            official application record
            Source null
            openfda application present
            false
            products

            Source passages and status connections

            Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

            Passage 1 · positive indication candidate
            application numbers
            1. BLA125703
            brand names
            1. TECARTUS
            classification reasons
            1. explicit_positive_indication_predicate
            2. tumor_or_malignant_hematology_words_in_positive_statement
            clinical review status
            pending
            content role
            positive_indication_candidate
            context span
            end
            407
            end exclusive
            true
            exact text
            1 INDICATIONS AND USAGE TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL). Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 1.1 Mantle Cell Lymphoma TECARTUS is indicated for the treatment of adult patients with relapsed or ref
            label id
            17c4a716-a22e-486d-b633-4be6c2453266
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
            start
            0
            current approval status
            not_reconciled
            duplicate text group
            dup-c094d11afa06d90edc33
            extraction review status
            automated_candidate_pending_source_review
            generic names
            1. BREXUCABTAGENE AUTOLEUCEL
            id
            ind-span-16b5887b6004e209c44b
            label id
            17c4a716-a22e-486d-b633-4be6c2453266
            positive predicate support span
            end
            114
            end exclusive
            true
            exact text
            is a CD19-directed genetically modified autologous T cell immunotherapy indicated
            label id
            17c4a716-a22e-486d-b633-4be6c2453266
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
            start
            33
            qualifier mentions
            1. context exact
              logous T cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL).
              kind
              age
              polarity
              not_inferred
              span
              end
              151
              end exclusive
              true
              exact text
              Adult patients
              label id
              17c4a716-a22e-486d-b633-4be6c2453266
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
              start
              137
            2. context exact
              1 INDICATIONS AND USAGE TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult
              kind
              biomarker
              polarity
              not_inferred
              span
              end
              82
              end exclusive
              true
              exact text
              CD19-directed genetically modified autologou
              label id
              17c4a716-a22e-486d-b633-4be6c2453266
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
              start
              38
            3. context exact
              therapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL).
              kind
              stage_or_setting
              polarity
              not_inferred
              span
              end
              200
              end exclusive
              true
              exact text
              relapsed or refractory mantle cell lymphoma
              label id
              17c4a716-a22e-486d-b633-4be6c2453266
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
              start
              157
            regulatory links
            1. candidate source span
              end
              207
              end exclusive
              true
              exact text
              1 INDICATIONS AND USAGE TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL).
              label id
              17c4a716-a22e-486d-b633-4be6c2453266
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
              start
              0
              fda indication exact
              Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
              fda source row index
              50
              fda source sha256
              8df28be8da28c19a2d63f9c7ada45adf8aa0a5f11be1a2b4df67ce8eea572def
              fda status record id
              fda-aa-b5d3c853ddc4e9301e35
              interpretation
              Source wording correspondence to a dated FDA status row; current approval not certified
              match method
              whole_indication_literal_normalized_substring
              matching review status
              source_comparison_only_clinical_review_pending
              scope relationship
              whole_fda_indication_text_present
              status category
              ongoing
              status event date
              2020-07-24
              supporting anchor spans
              schema version
              0.1.0
              source batch sha256
              0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
              source defined aliases
                source span
                end
                207
                end exclusive
                true
                exact text
                1 INDICATIONS AND USAGE TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL).
                label id
                17c4a716-a22e-486d-b633-4be6c2453266
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                start
                0
                source url
                https://api.fda.gov/drug/label.json?search=id%3A%2217c4a716-a22e-486d-b633-4be6c2453266%22
                spl effective date
                2026-06-16
                spl set id
                a16108c2-7ca7-45af-965e-54bda4713022
                spl version
                17
                structured fields status
                not_extracted_no_values_inferred_from_mentions
                structured indication
                age
                Source null
                approval pathway
                Source null
                biomarker and test
                Source null
                disease stage
                Source null
                limitations
                Source null
                line
                Source null
                prior therapy
                Source null
                regimen
                Source null
                tumor histology
                Source null
                use intent
                tumor_directed_candidate

                Read indication-specific status → · whole_fda_indication_text_present

                Passage 2 · positive indication candidate
                application numbers
                1. BLA125703
                brand names
                1. TECARTUS
                classification reasons
                1. inherited_predicate_from_same_label_section_requires_review
                2. tumor_or_malignant_hematology_words_in_positive_statement
                clinical review status
                pending
                content role
                positive_indication_candidate
                context span
                end
                503
                end exclusive
                true
                exact text
                TIONS AND USAGE TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL). Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 1.1 Mantle Cell Lymphoma TECARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). 1.2 Acute Lymphoblastic Leukemia TECARTUS is indicated for t
                label id
                17c4a716-a22e-486d-b633-4be6c2453266
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                start
                8
                current approval status
                not_reconciled
                duplicate text group
                dup-8db014a553e9bab283ad
                extraction review status
                automated_candidate_pending_source_review
                generic names
                1. BREXUCABTAGENE AUTOLEUCEL
                id
                ind-span-ec501bef8c34c43185f2
                label id
                17c4a716-a22e-486d-b633-4be6c2453266
                positive predicate support span
                end
                114
                end exclusive
                true
                exact text
                is a CD19-directed genetically modified autologous T cell immunotherapy indicated
                label id
                17c4a716-a22e-486d-b633-4be6c2453266
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                start
                33
                qualifier mentions
                1. context exact
                  Adult patients with relapsed or refractory B-cell precursor acute lymphobl
                  kind
                  age
                  polarity
                  not_inferred
                  span
                  end
                  222
                  end exclusive
                  true
                  exact text
                  Adult patients
                  label id
                  17c4a716-a22e-486d-b633-4be6c2453266
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                  start
                  208
                2. context exact
                  Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
                  kind
                  stage_or_setting
                  polarity
                  not_inferred
                  span
                  end
                  271
                  end exclusive
                  true
                  exact text
                  relapsed or refractory B-cell precursor acu
                  label id
                  17c4a716-a22e-486d-b633-4be6c2453266
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                  start
                  228
                regulatory links
                  schema version
                  0.1.0
                  source batch sha256
                  0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
                  source defined aliases
                    source span
                    end
                    303
                    end exclusive
                    true
                    exact text
                    Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
                    label id
                    17c4a716-a22e-486d-b633-4be6c2453266
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                    start
                    208
                    source url
                    https://api.fda.gov/drug/label.json?search=id%3A%2217c4a716-a22e-486d-b633-4be6c2453266%22
                    spl effective date
                    2026-06-16
                    spl set id
                    a16108c2-7ca7-45af-965e-54bda4713022
                    spl version
                    17
                    structured fields status
                    not_extracted_no_values_inferred_from_mentions
                    structured indication
                    age
                    Source null
                    approval pathway
                    Source null
                    biomarker and test
                    Source null
                    disease stage
                    Source null
                    limitations
                    Source null
                    line
                    Source null
                    prior therapy
                    Source null
                    regimen
                    Source null
                    tumor histology
                    Source null
                    use intent
                    tumor_directed_candidate
                    Passage 3 · positive indication candidate
                    application numbers
                    1. BLA125703
                    brand names
                    1. TECARTUS
                    classification reasons
                    1. explicit_positive_indication_predicate
                    2. tumor_or_malignant_hematology_words_in_positive_statement
                    clinical review status
                    pending
                    content role
                    positive_indication_candidate
                    context span
                    end
                    614
                    end exclusive
                    true
                    exact text
                    indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL). Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 1.1 Mantle Cell Lymphoma TECARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). 1.2 Acute Lymphoblastic Leukemia TECARTUS is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
                    label id
                    17c4a716-a22e-486d-b633-4be6c2453266
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                    start
                    104
                    current approval status
                    not_reconciled
                    duplicate text group
                    dup-cb62c7a4d6226061be01
                    extraction review status
                    automated_candidate_pending_source_review
                    generic names
                    1. BREXUCABTAGENE AUTOLEUCEL
                    id
                    ind-span-be9f1b9be895c03a94fa
                    label id
                    17c4a716-a22e-486d-b633-4be6c2453266
                    positive predicate support span
                    end
                    350
                    end exclusive
                    true
                    exact text
                    is indicated
                    label id
                    17c4a716-a22e-486d-b633-4be6c2453266
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                    start
                    338
                    qualifier mentions
                    1. context exact
                      le Cell Lymphoma TECARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
                      kind
                      age
                      polarity
                      not_inferred
                      span
                      end
                      386
                      end exclusive
                      true
                      exact text
                      adult patients
                      label id
                      17c4a716-a22e-486d-b633-4be6c2453266
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                      start
                      372
                    2. context exact
                      ARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
                      kind
                      stage_or_setting
                      polarity
                      not_inferred
                      span
                      end
                      435
                      end exclusive
                      true
                      exact text
                      relapsed or refractory mantle cell lymphoma
                      label id
                      17c4a716-a22e-486d-b633-4be6c2453266
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                      start
                      392
                    regulatory links
                    1. candidate source span
                      end
                      442
                      end exclusive
                      true
                      exact text
                      1.1 Mantle Cell Lymphoma TECARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
                      label id
                      17c4a716-a22e-486d-b633-4be6c2453266
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                      start
                      304
                      fda indication exact
                      Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
                      fda source row index
                      50
                      fda source sha256
                      8df28be8da28c19a2d63f9c7ada45adf8aa0a5f11be1a2b4df67ce8eea572def
                      fda status record id
                      fda-aa-b5d3c853ddc4e9301e35
                      interpretation
                      Source wording correspondence to a dated FDA status row; current approval not certified
                      match method
                      whole_indication_literal_normalized_substring
                      matching review status
                      source_comparison_only_clinical_review_pending
                      scope relationship
                      whole_fda_indication_text_present
                      status category
                      ongoing
                      status event date
                      2020-07-24
                      supporting anchor spans
                      schema version
                      0.1.0
                      source batch sha256
                      0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
                      source defined aliases
                        source span
                        end
                        442
                        end exclusive
                        true
                        exact text
                        1.1 Mantle Cell Lymphoma TECARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
                        label id
                        17c4a716-a22e-486d-b633-4be6c2453266
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                        start
                        304
                        source url
                        https://api.fda.gov/drug/label.json?search=id%3A%2217c4a716-a22e-486d-b633-4be6c2453266%22
                        spl effective date
                        2026-06-16
                        spl set id
                        a16108c2-7ca7-45af-965e-54bda4713022
                        spl version
                        17
                        structured fields status
                        not_extracted_no_values_inferred_from_mentions
                        structured indication
                        age
                        Source null
                        approval pathway
                        Source null
                        biomarker and test
                        Source null
                        disease stage
                        Source null
                        limitations
                        Source null
                        line
                        Source null
                        prior therapy
                        Source null
                        regimen
                        Source null
                        tumor histology
                        Source null
                        use intent
                        tumor_directed_candidate

                        Read indication-specific status → · whole_fda_indication_text_present

                        Passage 4 · positive indication candidate
                        application numbers
                        1. BLA125703
                        brand names
                        1. TECARTUS
                        classification reasons
                        1. explicit_positive_indication_predicate
                        2. tumor_or_malignant_hematology_words_in_positive_statement
                        clinical review status
                        pending
                        content role
                        positive_indication_candidate
                        context span
                        end
                        614
                        end exclusive
                        true
                        exact text
                        ractory B-cell precursor acute lymphoblastic leukemia (ALL). 1.1 Mantle Cell Lymphoma TECARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). 1.2 Acute Lymphoblastic Leukemia TECARTUS is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
                        label id
                        17c4a716-a22e-486d-b633-4be6c2453266
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                        start
                        243
                        current approval status
                        not_reconciled
                        duplicate text group
                        dup-704857b7d455225b53eb
                        extraction review status
                        automated_candidate_pending_source_review
                        generic names
                        1. BREXUCABTAGENE AUTOLEUCEL
                        id
                        ind-span-7f6ca74431359f1ddc52
                        label id
                        17c4a716-a22e-486d-b633-4be6c2453266
                        positive predicate support span
                        end
                        497
                        end exclusive
                        true
                        exact text
                        is indicated
                        label id
                        17c4a716-a22e-486d-b633-4be6c2453266
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                        start
                        485
                        qualifier mentions
                        1. context exact
                          blastic Leukemia TECARTUS is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphobl
                          kind
                          age
                          polarity
                          not_inferred
                          span
                          end
                          533
                          end exclusive
                          true
                          exact text
                          adult patients
                          label id
                          17c4a716-a22e-486d-b633-4be6c2453266
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                          start
                          519
                        2. context exact
                          ARTUS is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
                          kind
                          stage_or_setting
                          polarity
                          not_inferred
                          span
                          end
                          582
                          end exclusive
                          true
                          exact text
                          relapsed or refractory B-cell precursor acu
                          label id
                          17c4a716-a22e-486d-b633-4be6c2453266
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                          start
                          539
                        regulatory links
                          schema version
                          0.1.0
                          source batch sha256
                          0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
                          source defined aliases
                            source span
                            end
                            614
                            end exclusive
                            true
                            exact text
                            1.2 Acute Lymphoblastic Leukemia TECARTUS is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
                            label id
                            17c4a716-a22e-486d-b633-4be6c2453266
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            fe397737acfb15e614c22a84ff6b93764b638fbc4c9b6407c0f306813a200e93
                            start
                            443
                            source url
                            https://api.fda.gov/drug/label.json?search=id%3A%2217c4a716-a22e-486d-b633-4be6c2453266%22
                            spl effective date
                            2026-06-16
                            spl set id
                            a16108c2-7ca7-45af-965e-54bda4713022
                            spl version
                            17
                            structured fields status
                            not_extracted_no_values_inferred_from_mentions
                            structured indication
                            age
                            Source null
                            approval pathway
                            Source null
                            biomarker and test
                            Source null
                            disease stage
                            Source null
                            limitations
                            Source null
                            line
                            Source null
                            prior therapy
                            Source null
                            regimen
                            Source null
                            tumor histology
                            Source null
                            use intent
                            tumor_directed_candidate

                            Preserved source evidence · Not medical advice